Evaluation of ProC global assay in women with a history of venous thromboembolism on hormonal therapy

Thrombosis and Haemostasis

Volumn 96, Issue 5, 2006, Pages 578-583

  Sarig, Galit ^a   Aberbach, Irit ^a   Schliamser, Liliana ^a   Blumenfeld, Zeev ^a   Brenner, Benjamin ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Hormonal therapy; Oral contraceptive; ProC global assay; Thrombophilic risk factor

Indexed keywords

CONJUGATED ESTROGEN; HORMONE; ORAL CONTRACEPTIVE AGENT; PROTEIN C;

ADULT; AGE; AGED; ANALYTICAL EQUIPMENT; ANAMNESIS; ARTICLE; ASSAY; BLOOD CLOTTING; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIAGNOSTIC VALUE; FEMALE; HORMONAL THERAPY; HUMAN; LUNG EMBOLISM; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

ADULT; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; PROTEIN C; REAGENT KITS, DIAGNOSTIC; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 33751223842     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-05-0285     Document Type: Article

References (24)

1. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP Oral Contraceptives, hormone replacement therapy and thrombosis. Thromb Haemost 2001; 86: 112-23.
2. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-10.
3. Walker ID. Hormone replacement therapy and venous thromboembolism. Thromb Res 2005; 115 (Suppl 1): 88-92.
4. Vandenbroucke JP, Koster T, Briët E, et al. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
5. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
6. Simioni P, Sanson BJ, Prandoni P, et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
7. Olivieri O, Friso S, Manzato F, et al. Resistance to activated protein C in healthy women taking oral contraceptives. Br J Haematol 1995; 91: 465-70.
8. Henkens CM, Bom VJ, Seienen AJ, et al. Sensitivity to activated protein C; influence of oral contraceptives and sex. Thromb Haemost 1995; 73: 402-4.
9. Rosing J. Mechanisms of OC related thrombosis. Thromb Res 2005; 115 (Suppl 1): 81-3.
10. de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
11. Kraus M, Noah M, Fickenscher K. The PCAT - a simple screening assay for assessing the functionality of the protein C anticoagulant pathway. Thromb Res 1995; 79: 217-22.
12. Robert A, Eschwege V Hameg H, et al. Anticoagulant response to Agkistrodon contortrix venom (ACV test): a new global test to screen for defects in the anti-coagulant protein C pathway. Thromb Haemost 1996; 75: 562-6.
13. Dati F, Hafner G, Erbes H, et al. ProC Global: the first functional screening assay for the complete protein C pathway. Clin Chem 1997; 43: 1719-23.
14. Tripodi A, Akhavan S, Asti D, et al. Laboratory screening of thrombophilia. Evaluation of the diagnostic efficacy of a global test to detect congenital deficiencies of the protein C anticoagulant pathway. Blood Coag Fibrinol 1998; 9: 485-9.
15. Toulon P, Halbmeyer WM, Hafner G, et al. Screening for abnormalities of the protein C anticoagulant pathway using the ProC Global assay. Results of European multicenter evaluation. Blood Coag Fibrinol 2000; 11: 447-54.
16. Grand'Maison A, Bates SM, Johnston M, et al. 'ProC Global': a functional screening test that predicts recurrent venous thromboembolism. Thromb Haemost 2005; 93: 600-4.
17. Sarig G, Lanir N, Hoffman R, et al. Protein C global assay in the evaluation of women with idiopathic pregnancy loss. Thromb Haemost 2002; 87: 32-6
18. Heilmann L, von Tempelhoff GF, Pollow K. Pro C Global assay in the evaluation of women with history of severe pre-eclampsia or HELLP syndrome. Clin Appl Thromb Hemost 2002; 8: 319-24.
19. Sarig G, Younis JS, Hoffman R, et al. Thrombophilia is common in women with idiopathic pregnancy los and is associated with late pregnancy wastage. Ferti Steril 2002; 77: 342-7.
20. Toulon P, Adda R, Perez P. Sensitivity of the ProC Global assay for protein C pathway abnormalities Clinical experience in 899 unselected patients with venous thromboembolism. Thromb Res 2001; 104 93-103
21. Wu O, Robertson L, Langhorne P et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assess ment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17-25.
22. Gemmati D, Serino ML, Tognazzo S, et al. The reduced sensitivity of the ProC® Global test in protein S deficient subjects reflects a reduction in the associated thrombotic risk. Blood Coag Fibrinol 2001; 12: 691-7.
23. Rosing J, Tans G, Nicolaes GA, et al. Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol 1997; 97: 233-8.
24. Wu O, Robertson L, Twaddle S, et al. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.